• Home
    • StockRanks™
    • Platform
        • Research & Discuss
        • Editorial & Community
        • Learn & Improve
        • Webinars & Masterclasses
        • Stockopedia Academy
    • Reviews
    • Pricing
    Get startedLog in
    SectorsHealthcareBiotechnology & Medical ResearchInhibrx
    Picture of Inhibrx logo

    INBX — Inhibrx News Story

    $34.140.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMid CapMomentum Trap
    • Market Cap
      $1.79bn
    • Enterprise Value
      $1.74bn
    • Revenue
      $1.80m
    • Quality
    • Value
    • Momentum
    • StockRank™
    • StockReport™
    • Accounts
      • Balance sheet
      • Income statement
      • Cashflow statement
      • Dividend summary
    • News
    • INBX Dividends
    StockReport™
    Balance sheet
    Income statement
    Cashflow
    News
    INBX Dividends
    All News

    NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:33 AM

    Picture of Inhibrx logoInhibrx
    22/04/2026 14:33
    NASDAQ TRADE HALT  INBX.O  VOLATILITY TRADING PAUSE AT 09:33 AM
    

    Recent news on Inhibrx

    See all news
    • Inhibrx Q1 net loss narrows as R&D costs fall

      14/05/2026 21:09
    • Brief: Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy

      11/05/2026 13:57
    • Brief: Inhibrx to host webcast presentation to provide clinical update on INBRX-106 HexAgon study in first line HNSCC

      08/05/2026 21:03
    • Merck, rivals eye Inhibrx experimental cancer drug tied to Keytruda, sources say

      22/04/2026 19:53
    • U.S. STOCKS ON THE MOVE-Tesla, AT&T, Yesway

      22/04/2026 19:01

    Company

    • About us
    • Careers
    • Product Guide

    Our Coverage

    • Countries
    • Sectors
    • Ratios

    Top Stocks

    • UK Stocks
    • Australian Stocks
    • US Stocks

    Legals

    • Privacy Policy
    • Terms & Conditions
    • Disclaimer & FSG
    • Cookies
    Trustpilot
    Select a country/region:


    © Stockopedia 2026, Refinitiv, Share Data Services.

    *Past performance is no indicator of future performance, and testimonials are provided by third parties for informational purposes only and are not intended and should not be taken to be financial product advice. Performance returns are based on hypothetical scenarios and do not represent an actual investment.

    This site cannot substitute for professional investment advice or independent factual verification. To use Stockopedia, you must accept our Terms of use, Privacy and Disclaimer & FSG. All services are provided by Stockopedia Ltd, United Kingdom (company number 06367267). For Australian users: Stockopedia Ltd, ABN 39 757 874 670 is a Corporate Authorised Representative of Daylight Financial Group Pty Ltd ABN 77 633 984 773, AFSL 521404.